Cas9 News and Research

RSS

Risk factors for mortality among hospitalized patients with COVID-19

A new study by scientists at biotechnology company Genentech, Inc., and published on the preprint server medRxiv in September 2020 attempts to identify the factors which may shape the risk for death in COVID-19 disease.

27 Sep 2020

CRISPR screening identifies human host pathways that facilitate coronavirus infection

The human coronavirus family consists of 7 known pathogens, for which there are no approved vaccines or specific therapeutic options. Although the seasonal human coronaviruses - OC43, HKU1, 229E, and NL63 – only cause mild respiratory infections, three highly pathogenic coronaviruses that emerged in the last two decades revealed the pandemic potential of this family of viruses.

27 Sep 2020

Alzheimer’s disease-associated protective genetic variant enhances key functions of immune cells

A new study conducted by researchers at the University of Eastern Finland found that the PLCG2-P522R genetic variant, which protects against Alzheimer's disease, enhances several key functions of immune cells. The results obtained in the study highlight the importance of immune cells as a target of future development of new therapies for Alzheimer's disease.

25 Sep 2020

Michael Arciero joins ERS Genomics as Vice-President of Intellectual Property and Commercial Development

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced the appointment of Michael Arciero as Vice-President of Intellectual Property and Commercial Development.

23 Sep 2020

Common genetic variants may influence susceptibility to COVID-19

Researchers in the United States and Japan have conducted a study suggesting that a commonly occurring genetic variant influences susceptibility to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

23 Sep 2020

ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

17 Sep 2020

Researchers compare developed carriers for delivery of genome editing tools with existing analogs

Researchers from Peter the Great St.Petersburg Polytechnic University in collaboration with colleagues from the Pavlov University, ITMO University, and the University of Hamburg compared their developed carriers for delivery of genome editing (GE) tools with other available analogs.

16 Sep 2020

Curi Bio Announces Mantarray™ Platform for Analysis of 3D Engineered Muscle Tissues for Discovery of New Therapeutics

Curi Bio today announced the Mantarray™ platform for human-relevant 3D engineered muscle tissue (EMT) analysis.

From Curi Bio 16 Sep 2020

RCas9 gene therapy clears toxic RNA buildup in mouse model of myotonic dystrophy

Myotonic dystrophy type I is the most common type of adult-onset muscular dystrophy. People with the condition inherit repeated DNA segments that lead to the toxic buildup of repetitive RNA, the messenger that carries a gene's recipe to the cell's protein-making machinery.

14 Sep 2020

Cas9 News and Research

Risk factors for mortality among hospitalized patients with COVID-19

CRISPR screening identifies human host pathways that facilitate coronavirus infection

Alzheimer’s disease-associated protective genetic variant enhances key functions of immune cells

Michael Arciero joins ERS Genomics as Vice-President of Intellectual Property and Commercial Development

Common genetic variants may influence susceptibility to COVID-19

ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools

Researchers compare developed carriers for delivery of genome editing tools with existing analogs

Curi Bio Announces Mantarray™ Platform for Analysis of 3D Engineered Muscle Tissues for Discovery of New Therapeutics

RCas9 gene therapy clears toxic RNA buildup in mouse model of myotonic dystrophy

Two MDC scientists win ERC Starting Grants for pioneering research

New sequencing approach can detect rare mutation in large number of cells

Novel cell-based therapy holds promise for obesity and diabetes

New bioluminescent reporter developed to track DNA double stranded break repair

Researchers reproduce the pathogenesis of hereditary kidney disease from human iPS cells

Gene editing approach removes oral herpes

NIH awards $1.2 million grant to create humanized mice susceptible to COVID-19

Scientists create new mouse model of permanent neonatal diabetes

Horizon Discovery introduces single cell RNAseq-linked CRISPR screening service

Study shows how regulatory mechanisms contribute to formation of tissues in mouse embryo

CNIO and HKUST researchers identify how some gliomas acquire chemoresistance

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News